Teva leads call to secure Europe’s access to critical medicines and protect health sovereignty

Brussels, 26 June 2025 – Speaking at the Medicines for Europe Annual Conference, Michal Nitka, SVP Head Generics Europe & Global Head OTC at Teva Pharmaceuticals, highlighted the essential role of a resilient, competitive, and environmentally sustainable pharmaceutical industry in safeguarding patient access to medicines and strengthening Europe’s healthcare sovereignty. While advancing its innovative portfolio of medicines, Teva strongly believes in the vital role that generics and biosimilars play in supporting millions of patients across Europe.

“A strong, competitive, and sustainable pharmaceutical sector is vital not just for economic growth, but to protect patients across Europe,” said Mr Nitka. “Producing in Europe, means building a secure, future-ready healthcare system that works in the best interest of every patient.”

As the EU debates the Critical Medicines Act and other legislative efforts to secure supply and strategic autonomy, Teva is calling for forward-looking solutions to improve medicines supply across Europe:

Support European Manufacturing to Secure Supply: Building and maintaining strong pharmaceutical production in Europe is essential to securing the stable supply of critical medicines and building greater resilience against external geopolitical shocks. Procurement policies should treat manufacturing as a strategic asset for Europe and fully adopt multi-winner and multi-criteria tenders, rewarding those contributing to Europe’s resilience, transformation and competitiveness.

Advance a Unified Approach to Stockpiling and Data: A harmonised EU solidarity mechanism, supported by improved data sharing, is essential to reduce stock imbalances and promote the movement of medicines across the EU for a more stable and secure supply. Stockpiling is not a one size fits all solution. It should only be applied selectively, following thorough vulnerability assessments.

Unlock Supply Flexibility Through Digital Innovation: Embracing digital tools and AI can improve the flow of medicines across EU borders, helping to deliver faster, more flexible access for patients. Advancing e-leaflets and standardised packaging is a key step to achieving this.

Strengthen Existing Manufacturing Capabilities and Expertise: Europe’s future health security relies on sustaining and growing its existing manufacturing base.  Smart and accessible funding mechanisms are urgently needed to retain and expand manufacturing expertise and ensure Europe stays competitive and innovative in a global market.

Teva is committed to continued investment in European production, research and development, innovation, and jobs - while upholding the highest regulatory standards and environmental responsibility.

Despite a 30% rise in average consumer prices over the past decade, the average list prices for generic and biosimilar medicines have declined by 8%. Combined with challenging and complex regulatory pressures and cost inflation, this imbalance threatens the industry’s ability to produce critical medicines in Europe. A fairer balance between regulatory burden and economic viability must be restored.

Teva operates across the full spectrum of innovation to continuously better health worldwide. By following the science, Teva drives the discovery and development of modern therapies, as well as innovating throughout its established portfolio. As one of the largest global manufacturers of generic and innovative medicines, Teva makes a significant contribution to medicines in the EU region:

• 96% of Teva’s medicines sold in Europe are produced locally across more than 20 manufacturing sites, ensuring supply chain stability even during crises.

• Teva supplies 42% of the medicines on the EU Critical Medicines List, reinforcing the region’s healthcare sovereignty.

• In 2024 alone, Teva helped save European healthcare systems an estimated €3 billion, enabling reinvestment in innovative therapies.

-ends-

About Teva Pharmaceuticals:

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, supported by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we are investing significantly in R&D across generics, biosimilars and innovative medicines – with growing biopharmaceutical capabilities. Our research supports a pipeline focused on delivering better outcomes for patients in Europe and globally. Learn more at www.tevapharm.com.

About the Medicines for Europe Conference:

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. For more information, please follow www.medicinesforeurope.com and on LinkedIn and X @medicinesforEU.

Media Contact:
Alec Harris
Senior Account Manager, Four Agency
alec.harris@four.agency
+44 7710 736865